These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2798529)

  • 1. Delayed appearance of facial tics following chronic fluphenazine administration to guinea pigs.
    Weinstein D; See RE; Ellison G
    Pharmacol Biochem Behav; 1989 Apr; 32(4):1057-60. PubMed ID: 2798529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroleptic-induced oral movements in rats: methodological issues.
    Levy AD; See RE; Levin ED; Ellison GD
    Life Sci; 1987 Sep; 41(12):1499-506. PubMed ID: 2887997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pathophysiology of tardive dyskinesia.
    Klawans HL; Carvey P; Tanner CM; Goetz CG
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central administration of the neurotensin receptor antagonist SR48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia.
    McCormick SE; Stoessl AJ
    Neuroscience; 2003; 119(2):547-55. PubMed ID: 12770567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of subthalamic nucleus lesions in a putative model of tardive dyskinesia in the rat.
    Stoessl AJ; Rajakumar N
    Synapse; 1996 Nov; 24(3):256-61. PubMed ID: 8923666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A monkey model of tardive dyskinesia (TD): evidence that reversible TD may turn into irreversible TD.
    Kovacic B; Domino EF
    J Clin Psychopharmacol; 1982 Oct; 2(5):305-7. PubMed ID: 6890075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluphenazine decanoate and tardive dyskinesia: a possible association.
    Csernansky JG; Grabowski K; Cervantes J; Kaplan J; Yesavage JA
    Am J Psychiatry; 1981 Oct; 138(10):1362-5. PubMed ID: 7294195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of oral movements in rats during and after chronic haloperidol and fluphenazine administration.
    See RE; Levin ED; Ellison GD
    Psychopharmacology (Berl); 1988; 94(3):421-7. PubMed ID: 3128820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rats administered chronic neuroleptics develop oral movements which are similar in form to those in humans with tardive dyskinesia.
    Ellison G; See RE
    Psychopharmacology (Berl); 1989; 98(4):564-6. PubMed ID: 2570435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of fluphenazine decanoate (a long-acting phenothiazine) on serum prolactin and amphetamine-induced behavioural changes.
    Merali Z; Toth G
    Pharmacol Biochem Behav; 1982 Jul; 17(1):25-30. PubMed ID: 7122665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D(1A) receptor function in a rodent model of tardive dyskinesia.
    Van Kampen JM; Stoessl AJ
    Neuroscience; 2000; 101(3):629-35. PubMed ID: 11113312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluphenazine-induced acute and tardive dyskinesias in monkeys.
    Kovacic B; Domino EF
    Psychopharmacology (Berl); 1984; 84(3):310-4. PubMed ID: 6440175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia.
    McCormick SE; Stoessl AJ
    Neuroscience; 2002; 112(4):851-9. PubMed ID: 12088744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spontaneous dyskinesia in subjects with schizophrenia spectrum personality.
    Cassady SL; Adami H; Moran M; Kunkel R; Thaker GK
    Am J Psychiatry; 1998 Jan; 155(1):70-5. PubMed ID: 9433341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia.
    Stoessl AJ; Polanski E; Frydryszak H
    Mov Disord; 1993 Oct; 8(4):445-52. PubMed ID: 7901759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dopamine agonists in tardive dyskinesia.
    Smith RC; Tamminga CA; Haraszti J; Pandey GN; Davis JM
    Am J Psychiatry; 1977 Jul; 134(7):763-8. PubMed ID: 869053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of a primate model for tardive dyskinesia.
    Bárány S; Häggström JE; Gunne LM
    Acta Pharmacol Toxicol (Copenh); 1983 Feb; 52(2):86-9. PubMed ID: 6846025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ethanol in a putative rodent model of tardive dyskinesia.
    Stoessl AJ
    Pharmacol Biochem Behav; 1996 Jul; 54(3):541-6. PubMed ID: 8743627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
    Bishnoi M; Chopra K; Kulkarni SK
    Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.